IMUNON, Inc. (Nasdaq: IMNN) reports significant progress in their Phase 3 OVATION 3 Study, advancing towards a potential BLA filing for ovarian cancer treatment. Strong enrollment and positive outcomes from previous studies show promise for IMNN-001. New data from the ongoing MRD study further supports the potential breakthrough in immunotherapy for ovarian cancer. The TheraPlas platform shows potential for expansion beyond ovarian cancer treatment. Financial discipline and strategic execution have positioned IMUNON for success in 2026. With promising results and ongoing trials, IMUNON aims to redefine cancer care and create sustainable shareholder value.

Read more at GlobeNewswire: IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL